Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create Precision Biologics, this includes next generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as novel cytokines to modulate the immune system and long acting therapeutic peptides for metabolic and cardiovascular disease, all designed to have improved pharmacologic properties and novel biological activity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/10/20 | $200,000,000 | Crossover Financing |
Adage Capital Partners BlackRock Cormorant Asset Management Fidelity Management & Research Company HBM Healthcare Investments Invus Suvretta Capital Management | undisclosed |
